The invention relates to crystalline anhydrous forms, crystalline solvate forms and/or salt forms including crystalline salt forms of {(S)-3-[6-(6-methoxy-5-methyl-pyridin-3-yl)-5,6,7,8- tetrahydro-pyrido[4,3-d]pyrimidin-4-yloxy]-pyrrolidin-1-yl}-(tetrahydro-pyran-4-yl)-methanone or salt forms including crystalline salt forms of 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl- pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-on pharmaceutical compositions and combinations including these forms as well as to methods of using these forms, including their pharmaceutical compositions and combinations for the treatment of diseases.Cette invention concerne des formes anhydres cristallines, des formes solvates cristallines et/ou des formes sels comprenant les formes sels cristallines de la {(S)-3-[6-(6-méthoxy-5-méthyl-pyridin-3-yl)-5,6,7,8- tétrahydro-pyrido[4,3-d]pyrimidin-4-yloxy]-pyrrolidin-1-yl}-(tétrahydro-pyran-4-yl)-méthanone ou les formes sels comprenant les formes sels cristallines de la 1-{(S)-3-[6-(6-méthoxy-5-trifluorométhyl- pyridin-3-yl)-5,6,7,8-tétrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one des compositions pharmaceutiques et des combinaisons contenant ces formes ainsi que des procédés dutilisation desdites formes, y compris leurs compositions pharmaceutiques et combinaisons pour le traitement des maladies.
